CCWM
NBIX icon

Cassaday & Co Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Cassaday & Co Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.8K Hold
254
– – ﹤0.01% 649
2026
Q1 		$33.5K Buy
+254
New +$33.7K ﹤0.01% 695

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Cassaday & Co Wealth Management's NBIX Position: Q2 2026 in Review

Cassaday & Co Wealth Management held its Neurocrine Biosciences (NBIX) position steady in Q2 2026 at 254 shares worth $42.8K. The position accounts for ﹤0.01% of the portfolio, ranked #649.

Cassaday & Co Wealth Management first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Cassaday & Co Wealth Management held 254 shares of Neurocrine Biosciences worth $42.8K as of Q2 2026.
  • Cassaday & Co Wealth Management left its Neurocrine Biosciences share count unchanged in Q2 2026.
  • Neurocrine Biosciences made up ﹤0.01% of Cassaday & Co Wealth Management's portfolio in Q2 2026, its #649 holding.
  • Cassaday & Co Wealth Management first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.